# Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

> **NCT00813423** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Adult Solid Neoplasm

## Interventions

- **DRUG:** Hydroxychloroquine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00813423
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-19
- **Primary completion:** 2023-07-18
- **Final completion:** 2023-07-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813423, "Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00813423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*